Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction June 24, ...

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for ...

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer's disease, including clinical, biomarker and safety results for Biogen's investigational tau-targeting ASO, following topline ...

Ionis Pharmaceuticals draws attention after a rare-disease therapy license agreement, keeping its RNA-targeted medicine ...

Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar ...

Great. Good morning, everyone. Thank you so much for joining us. It's my pleasure to introduce Ionis. And with us, we have Brett Monia, CEO. Brett, thank you for being here. So to start here, you've ...

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ionis Pharmaceuticals IONS reported third-quarter 2025 adjusted loss per share of 61 cents, much narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company ...

Marquis Who's Who honors David J. DePorter, DDS, for excellence in dentistry. Dr. DePorter has completed over five decades of service and is recognized as a Top Professional in the field. Throughout ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, ...